key: cord-0880184-wcylgomo
authors: Focosi, Daniele; Franchini, Massimo
title: SARS‐CoV‐2 and the safety of blood donations: Time for a brave revision?
date: 2022-03-21
journal: Transfusion
DOI: 10.1111/trf.16818
sha: d5efa0452f30a8c175be6feb4379234e1678c59a
doc_id: 880184
cord_uid: wcylgomo

nan

Since the beginning of the COVID-19 pandemic, most of the regulatory authorities have implemented precautionary measures to prevent transmission of infection by transfusion of blood components, including not only deferral of donors positive or at risk, but also discarding units collected from donors who tested positive for SARS-CoV-2 in the days following donation (post-donation information-PDI). The World Health Organization still recommends that "Blood and components collected within 14 days prior to disease onset in the donor or collected within 14 days subsequent to contact exposure may be recalled as a precautionary measure." 1 The European CDC is still recommending that "Donor information on the occurrence of confirmed or probable COVID-19 within 72 hours after blood donation should trigger the discarding of donated blood and blood components, unless they have been treated with approved pathogen reduction technology." 2 India is still mandating discard if positivity occurs in the 28 days after donation (accessed online at: https://www.mohfw.gov.in/pdf/ 2ndNBTCGuidanceinLightofCOVID19Pandemic.pdf on January 13, 2022). The US FDA did not specify such a scenario in its guidelines. 3 The rationale for such a decision about a respiratory pathogen was mostly overprotection, since the time that COVID-19 was discovered no case of transfusion-transmitted human sarbecovirus had ever been recorded, viremia from SARS-CoV-2 had been almost exclusively observed in severe inpatients (unable to donate), and was low-grade and transient. Despite blood surveillance during a pandemic can be challenging (e.g., making it difficult to distinguish transfusion-transmitted from non-transfusion transmitted infections), to date no confirmed case of transmission has been recorded after transfusion of a SARS-COV-2 RT-PCR positive unit. 4 Despite that, most regulatory authorities are still maintaining the initial recommendations as a precautionary safety measure. Under the current pandemic wave driven by the variant of concern Omicron, most countries are experiencing a ravaging spread, locking down up to 10% of the population at a given time (either as positive cases or as cases requiring quarantine after exposure to a confirmed case): such lockdowns proportionally affecting blood donors (and also blood collection staff), creating a shortage of blood components in already stressed systems. Under such circumstances, units collected from asymptomatic donors later discovered as either positive for SARS-CoV-2 or as high-risk contacts of confirmed cases represent a substantial number of units (up to 3% in our practice). These authors work in Italy, where Directive 797/2020 (issued on March 26, 2020) similarly mandated discarding units from donors who tested SARS-COV-2 positive within 14 days since donation. 5 On January 10, 2022, 2 years into the pandemic, we formally asked the Italian National Blood Center to update the Directive in sight of revised knowledge about SARS-CoV-2 and the shortage of blood components in the Italian system. On January 11, 2022, the National Blood Center promptly issued a new recommendation (756/2022) stating "no action is required" on blood components collected from donors who either tested positive or reported a high-risk contact with a positive subject in the 7 days following donation (accessed online at http://www.centronazionalesangue.it/ wpcontent/uploads/2022/01/2022_0000756_Aggiornamen to-misure-di-prevenzione-della-trasmissione-dellinfezioneda-SARS-CoV-2_PDI-signed.pdf on January 13, 2022), hence granting their clinical usage. Such changes are needed at this time, and we hope more countries follow the Italian model, while preserving attention on potential transmission events.

Hypersensitivity transfusion reactions to platelet concentrate: a retrospective analysis of the French hemovigilance network

Adding to platelet safety and life: platelet additive solutions

Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion

Platelets treated with pathogen reduction technology: current status and future direction

Platelet additive solutions: a review of the latest developments and their clinical implications

COVID-19) pandemic and on the collection of COVID-19 convalescent plasma. Interim guidance

COVID-19) and supply of substances of human origin in the EU/EEA -Second update

Updated information for blood establishments regarding the COVID-19 pandemic and blood donation

No evidence of SARS-CoV-2 transmission through transfusion of human blood products: a systematic review

Aggiornamento misure di prevenzione della trasmissione dell'infezione da nuovo Coronavirus (SARS-CoV-2) mediante la trasfusione di emocomponenti labili